Expression of OCT4 Stem Cell Marker in Benign Prostatic Hyperplasia and Normal Tissue Around the Prostatic Carcinoma in a Sample of Iraqi Patients

Khalida I. Noel¹, Mustafa M. Ibraheem¹, Basim S. Ahmed², Ahmed F. Hameed¹, Nibras H. Khamees¹, Sameh S. Akkila¹

¹Department of Anatomy, ²Department of Pathology, College of Medicine, Al-Mustansiriyah University, Baghdad

ABSTRACT

Objective: Prostatic diseases (benign and malignant) are broadly widespread in the world. Benign prostatic hyperplasia is a chronic entity reflected by enlarged prostatic tissue, triggering inferior urinary tract complaints. On the other hand, prostate cancer, is the second most common cancer in men and the fourth utmost commonly happening cancer generally. OCT4 referred to as octamer binding transcription factor 4, also recognized as POU5F1 (POU domain class 5 transcription factor 1), is a protein that in humans is coded by the POU5F1 gene. This protein is analytically elaborate in the self-renewal of undifferentiated embryonic stem cells. As such, our work is designed to evaluate the immunohistochemical examination of OCT4 expression in the prostatic epithelium in cases of benign prostatic hyperplasia (BPH) and in the epithelium of prostatic adenocarcinoma microenvironment (NPCA).

Patients and Methods: The prostate samples were acquired from 50 BPH patients, and 50 prostatic cancer patients. The samples were managed for immunohistochemical examination of OCT4 expression.

Results: Statistical analysis revealed significant difference in the staining percentage between the BPH and NPCA group (P-value=0.009), and there was significant staining expression of OCT4 in NPCA group as compared to BPH group (P-value=0.000). Also, there was significant elevation of the total score of OCT4 in NPCA group (P-value=0.036) as compared with BPH group.

Conclusions: OCT4 is over expressed in normal tissue around prostatic carcinoma as compared to benign tissue in BPH, and thus OCT4 can be used as a stem cell marker for prostatic tissue tuomorigenicity.

Received: 18 June 2019, Accepted: 21 September 2019

Key Words: BPH, immunohistochemistry, OCT4, prostatic cancer.

Corresponding Author: Khalida I. Noel, PhD, Human Anatomy Department, College of Medicine, Mustansiriyah University, Baghdad, Iraq, Tel.: +964 7701658890, E-mail: khalidanoel79@gmail.com

ISSN: 1110-0559, Vol. 43, No. 1

INTRODUCTION

Benign prostatic hyperplasia is a chronic entity reflected by enlarged prostatic tissue, triggering inferior urinary tract complaints. The prevalence rises from nearly 50% at age of 60 to 90% in males older than 85 years¹⁰.

On the other hand, prostate cancer, is the second most common cancer in men and the fourth utmost commonly happening cancer generally. There were 1.3 million new cases in 2018 appeared all over the world²⁰. The number of new cases rises every year, while the rate of mortality is quite continuous. This can be credited to the fact that diagnostic procedures for early recognition of this disease are enhanced and allow earlier stages of the disease to be confined³⁰.

There are several genetic, hormonal, and inflammatory mechanisms that have all been displayed to be common pathophysiological active mechanisms for the appearance of both BPH and prostatic carcinoma (PCa), thus linking these diseases together⁰. However till now, on a cellular and molecular points, there is no clear cut data for change of BPH tissue into an oncological disease which is the principle aim of the current study. Furthermore, more research is required to fully expose the underlying molecular pathways behind prostatic diseases. This is essential to improve future treatment plans for both diseases³⁰.

OCT4 referred to as octamer binding transcription factor 4, also recognized as POU5F1 (POU domain class 5 transcription factor 1), is a protein that in humans is coded by the POU5F1 gene. This protein is analytically elaborate in the self-renewal of undifferentiated embryonic stem cells⁰. As such, it is usually used as an indicator for undifferentiated cells. Expression of OCT4 must be thoroughly organized; higher or lower level will cause differentiation of the cells⁰. However, OCT4 isoforms could be recognized also, and they differ in their expression; that OCT4B is expressed in the cytoplasm of cells, while OCT4A seen in the nucleus⁰. Both isoforms have the same DNA with its C terminal domains, but differ in N terminal domains⁰.
OCT4 IN BPH AND NORMAL TISSUE AROUND PROSTATIC CARCINOMA

It is well documented that higher expression of OCT4, Nanog and SOX2, separately or together could lead to tumorigenicity, cancer metastasis, and sometimes distant relapse after chemoradiotherapy in many kinds of cancer[6,7]. Over expression of OCT4 was noticed in Prostate cancer[8] and Breast tumor stem cells[9]. OCT4 plays a serious part in the existence of these cancer cells. In general, these transcription factors are mainly repeatedly highly expressed in poorly differentiated cancers; if compared to those well differentiated malignancy and expression level of these “stemness” related factors drops with the more differentiation of cells[10].

AIMS OF THE STUDY

This study aimed to assess the difference in OCT4 expression in BPH and prostatic carcinoma microenvironment.

Methods

Patients

The present work started from February 2018 to March 2019 in Al-Yarmok teaching hospital in Baghdad city of Iraq (histopathology unit) with two private histopathological labs. The revision was conducted on human prostatic tissue specimens received from patients attending this hospital.

A total number of 100 specimens were selected for the study, some were prospective, with a majority of retrospective samples acquired from archives of histopathology units of those labs and hospital.

The specimens were divided as follows

Fifty primary prostatic carcinoma tissue samples were obtained from surgical resection of the prostate, normal prostatic tissues excised within the safety margin (NPCA) (normal epithelial specimens ≥ 5 cm distant from the tumor margin, which is from the intact tissue during the operation)[11]. These specimens featured Gleason scores from 6 to 10 and fifty tissue specimens comprising benign prostatic hyperplasia (BPH) were gained from transurethral resection surgery.

Patients were divided into two groups namely normal adjacent to cancer (NPCA) including 50 patients known to have prostatic adenocarcinoma, their age ranged from 55-82 years with mean age 70 years. Another 50 patients who had BPH and their age range between 60-86 years with mean age 71 years.

Ethical agreement for the work was gained from the ethical committee of Al-Yarmok teaching hospital supported by written consent from the patients. The pathological diagnosis of prostatic carcinoma and BPH was established by reviewing a freshly prepared haematoxylin and eosin stained slides.

Immunohistochemistry

For each sample 2 serial sections were selected, each with 4 micrometers thickness. The first section was placed on an ordinary slide and stained by haematoxylin and cosin stain to confirm the diagnosis and to define the histological types and grades for the tumor. The second section was placed on the positively charged slide for immunohistochemical staining with anti-OCT4 antibody (Primary antibody from Abnova, Gene ID: 5460|18999|294562, Code PAB12773, Rabbit anti-human polyclonal raised against synthetic peptide of POU5F1, no specific isoform). The secondary detection kit (Abcam) code ab64261 rabbit specific HRP/DAB were used.

Formalin fixed samples and paraffin embedded tissue sections were dewaxed using xylene, and progressively hydrated. Antigen retrieval was done by pressure cooking using citrate buffer for 20 minutes. The primary anti-OCT4 antibody was diluted as 1:200 using a reducing dilution buffer (Abcam code ab64211) and kept warm at room temperature for 30 minutes[12].

Detection achieved by means of labeled streptavidin-biotin from Abcam secondary detection kit, followed by DAB and chromogen staining. The slides were briefly counterstained with haematoxylin and mounted by DPX[13].

Evaluation of the immunohistochemical staining

All tissues were evaluated blindly (without prior knowledge of the type of the sample or the age of the patient). Anti-OCT4 staining showed distinct nuclear brown IHC staining.

The accuracy of the positive and strongly positive categories was further tested and confirmed by ranking each slide from the lowest to highest intensity and extent of staining and location was also revealed for each marker. The slides were examined with low power microscope 10X to determine the regions of highest staining, if they show no staining at low power re-examination was done by high power 40X to determine area of weak staining, 5 fields of each slide were examined and scored semiquantitatively by calculating the proportion of positive staining cells over the total number of cells examined (%) and samples were graded according to the extent of staining and intensity[13].

The index was evaluated by multiplying the cell percentage with the intensity. Indices were determined by counting the number of positive nuclei among ≥300 cells in high-power fields and were indicated as percentages. Positive cells were evaluated for their intensity of immunoreactivity on a 0 - 3+ scale.

Percentage and intensity of staining were calculated as follows[14]:

Staining intensity was given scoring as:

0 (no staining), 1+ (weak), 2+ (moderate) and 3+ (strong).

Staining extent (percentage) was categorized by percentage:

0 = nil, 1= < 10% of cell stained positively, 2= 10-50%, 3= > 50%
Final IHS (total score) calculated by multiplying the intensity by percentage (0-3)\textsuperscript{[13]}

These was done by using double blind method for calculating both intensity and percentage and confirmed by using computerized (Immunohistochemical Profiler Plugin and Macro in Image J) method.

Quality Control

Positive control

Human adrenal gland tissue was used as a positive control for OCT4 which had been confirmed to overexpress OCT4\textsuperscript{[14]}.

Negative control

It was done by deleting the primary antibody and adding antibody diluent alone in the same slide and follows the same steps in IHC\textsuperscript{[13]}.

Statistical analysis

Statistical analysis was achieved by using the SPSS – (Statistical Packages for Social Sciences) V24. Categorical variables were evaluated by evaluation of percentage, mean, and range (min-max values). The qualitative data were examined using Pearson Chi–square test (X2 –test), and independent sample t-test.

RESULTS

Age distribution

The mean age of BPH group was (71.14±6.3) with the range of (60-86 years). The mean age of NPCA group was (69.76±7.9) with the range of (55-82 years). There were no statistical significance among the mean age of these groups (p value = 0.097) (Figure 1).

Immunohistochemical (IHC) expression of OCT4

The staining percentage of OCT4

OCT4 is a nuclear expressed marker, the percentage of staining of OCT4 in BPH group was (36.7±32.93), while in the NPCA group was (51.9±22.97). Therefore comparing the percentage of staining between the two groups was statistically significant P-value=0.009, with OCT4 was more expressed in the NPCA group as stated in (Figure 2).

The staining intensity of OCT4

In BPH group, there were 18 out of 50 samples (36%) that showed the negative expression (0) of OCT4. On the other hand, 15 out of 50 samples (30%) showed weak expression (1+) of OCT4 stem cell marker. Moderate staining expression (2+) were obtained in 10 out of 50 samples of BPH group (20%), while strong staining intensity (3+) were exhibited in 7 out of 50 samples (14%). The intensity scores are shown in (Figures 3 and 4) and the intensity of OCT4 epithelial cells expression in BPH tissue are shown in (Figures 5-8).

In NPCA group, only 1 out of 50 samples (2%) showed no expression of OCT4 (0). Whereas 15 out of 50 samples (30%) showed weak intensity (1+) of OCT4, and 25 out of 50 samples (50%) moderately express OCT4 (2+). On the other hand, 9 out of 50 NPCA samples (18%) displayed strong staining intensity (3+) of OCT4 stem cell marker. The intensity scores are shown in (Figures 3 and 4) and the intensity of OCT4 epithelial cells expression in BPH tissue are shown in (Figures 9-12).

Therefore, OCT4 had more intense positive signals (2+, 50%) in the NPCA group than in the BPH group and the difference was statistically significant with P-value=0.000 as shown in (Figure 3).

The total score of OCT4

Total score of 50 samples in BPH group, the mean and standard deviation of OCT4 marker was (0.71±0.28), and in the NPCA group (50 samples) was (1.06±0.77). So, OCT4 had a higher score in the NPCA group (P-value=0.036) as appeared in (Figure 4).

**Fig. 1:** Age distribution according to prostatic disorder (Bars represent mean & error bars= standard deviation)

**Fig. 2:** OCT4 staining percentage according to prostatic disease. **P-value < 0.01**
**Fig. 3:** Staining intensity of OCT4 according to prostatic disease. **P-value** < 0.01

**Fig. 4:** Total score of OCT4 expression in prostatic disease. *P-value* < 0.05

**Fig. 5:** Negative immunohistochemical expression of OCT4 in prostatic cell nuclei of BPH group. X400

**Fig. 6:** Immunohistochemical expression of OCT4 in BPH tissue shows 1+ weak nuclear reactivity (black arrows) of OCT4 polyclonal antibody. X400

**Fig. 7:** Immunohistochemical expression of OCT4 in BPH tissue shows 2+ nuclear moderate reactivity (black arrows) of OCT4 polyclonal antibody. X400

**Fig. 8:** Immunohistochemical expression of OCT4 in BPH tissue shows 3+ strong nuclear reactivity (black arrows) of OCT4 polyclonal antibody. X400
Fig. 9: Negative immunohistochemical expression of OCT4 in nuclei of normal tissue around PCa in NPCA samples. X400

Fig. 10: Immunohistochemical expression of OCT4 in NPCA group shows 1+ weak nuclear reactivity (black arrows) of OCT4 polyclonal antibody. X400

Fig. 11: Immunohistochemical expression of OCT4 in NPCA group shows 2+ moderate nuclear reactivity (black arrows) of OCT4 polyclonal antibody. X400

Fig. 12: Immunohistochemical expression of OCT4 in NPCA group shows 3+ strong nuclear reactivity (black arrows) of OCT4 polyclonal antibody. X400

DISCUSSION

Age distribution

Benign prostatic hyperplasia (BPH) is one of the most common disorders and major reason of sickness in old males which may produce bladder outflow blockade and inferior urinary tract signs[15]. The occurrence of BPH is related to age[16], in that the occurrence of hyperplastic changes of BPH in autopsy readings increases from approximately 20% in males aged 41-50 years, to 50% in males aged 51-60, and to > 90% in males older than 80[17]. More than 70% of the male population aged over 60 has medical or laboratory histological evidence of BPH.

Prostate cancer (PCa) is the most prevalent occurring male non-cutaneous tumor in the Western world[18,19] and the fourth malignant tumor affecting Iraqi men[20]. Considerate etiologies of both conditions is essential to decreasing the subsequent problem of illness and death.

The appearance of BPH upsurges severely with increasing age. The frequency of PCa also noticeably rises with age, being three times of extent higher for the age range from 40–79 years than for those aged less than 40 years[21,22]. There is a lot of correlation in the epidemiological reasons of BPH and PCa[23], but the ultimate risk factor for both illnesses is increasing the age of individuals.

Our results were in line with previous explanations of literatures[15,17,19,20,22,23] that showed an increasing incidence of both BPH and prostatic carcinoma in the ages above 60, after that age; the chance of developing PCa becomes more common than any other cancer in males[24]. There was no statistically significant difference between the age of cases with BPH than those with prostatic carcinoma in our work.

Expression of OCT4 in BPH and NPCA groups

Octamer 4 relates to the family of Pit-Oct-Unc-domain transcription factors and had been expressed in embryonic stem cell and germ cells[25]. A number of researches had
shown that OCT4 is crucial in retaining the self-renewal and pluripotency of embryonic stem cells\(^{[28]}\). Formally, it has also been revealed that cancer cells that expressed OCT4 may be fundamental in cancer development\(^{[27]}\).

The gene, OCT4, is one of an essential regulatory network, and is necessary for embryogenesis, pluripotency and self-renewal of cells\(^{[29]}\). OCT4 preserves pluripotency in embryogenesis; the up regulation of OCT4 marks in differentiation to the primitive endoderm and mesoderm, while downregulation encourages the decline of pluripotency and dedifferentiation into the trophectoderm\(^{[28]}\). A recent study examined the role of OCT4 as a wholesome stem cell marker by viewing its appearance in differentiated cells\(^{[29]}\). The important transcriptional regulator OCT4 preserves “stemness” condition.

Cancer stem cells had been recognized in a range of many malignancies\(^{[14]}\). They are a minor group of cancer cells with stem cell features, which are a probable cause of recurrence in malignant patients\(^{[30]}\). Earlier readings had also recommended that certain tumors, as well as prostate cancer\(^{[14,31]}\), expressed OCT4 concurrently\(^{[32,33]}\), and its expression has been linked with the differentiation of tumors\(^{[14]}\). This gene is important for cancer cell survival\(^{[33]}\), that claims the significance of tumor stem and progenitor cells in prostatic carcinogenesis. This higher score of appearance is not essentially related with stem cell behavior\(^{[30]}\), but might be related to the deregulation proteins that deliver certain kind of growing benefit to cell behavior\(^{[30]}\), yet many pluripotency markers, like CD117, CD44 and cytokeratin 34β\(^{[14]}\) might grow from transformed benign glandular tissues. OCT4 may be fundamental in cancer development but negative histological biopsy, documentation of field cancerization could deal the suspected zones by surgeons for repeated biopsy.

The source of prostate cancer origin remains unidentified and has taken us to a series of theories\(^{[44]}\). Prostatic adenocarcinomas are often multifocal, show the identical immunohistochemical outline as benign glandular tissues, and loss markers of basal cell, such as p63 and cytokeratin 34β\(^{[45]}\). This specifies that prostatic cancer might grow from transformed benign glandular tissues. Yet, many pluripotency markers, like CD117, CD44 and Oct3/4, had been revealed to be expressed in prostatic cancer, demonstrating that prostate cancer might arise from shared stem cell like or intermediate cells\(^{[46]}\).

According to the findings of some researchers, immunohistochemical appearance of OCT4 isoforms associated with pathological and biochemical considerations, predominantly biochemical recurrence-free survival. Cases with high levels of OCT4B expression had lower level of Gleason scores and reduced possibility of suffering biochemical relapse\(^{[47]}\). OCT4A- OCT4B- cases had the shorter biochemical recurrence-free survival, and positive expression of OCT4B was not dependent on Gleason score\(^{[35]}\). They decided that OCT4B expression was a stronger marker of good prediction, and the existence of it was related with a reduced probability of biochemical failure. Accordingly, OCT4B could symbolize a potent experimental prognostic factor for PCA Patients\(^{[47]}\). Though, OCT4 is a nuclear marker and appeared clearly in the nuclei of BPH and NPCA group cases of this work, but the difference in the OCT4 isoforms might demonstrate the OCT4 in both nucleus and cytoplasm of the epithelial cells. OCT4A antibody displayed specific nuclear staining\(^{[48]}\). Alternatively, OCT4B marker produced specific cytoplasmic expression in cancer cells and OCT4 antibody produced cytoplasmic and nuclear staining\(^{[47]}\). Gao et al. explained that the OCT4B isoform is up regulated underneath genotoxic tension, supporting apoptosis of cell by p53\(^{[48]}\). This kid of cell strain produces DNA damage and resulted in DNA mutations and tumorigenesis; cells might reply to DNA damage in 2 ways: either DNA apoptosis or repair; when the harm is repairable, cells might arrest cell cycle to adding more time for DNA repair, and when the harm is irreparable, they go on apoptosis to avoid that damaged DNA from being delivered on\(^{[47]}\). Accordingly, the elevation of apoptosis by OCT4B creates a protective appliance all over the entire entity. Conversely, cells expressing OCT4A had hardly been documented in human malignant and benign prostate tissues\(^{[47]}\). The number of these cells expressed OCT4A had been revealed to rise in prostate adenocarcinoma with higher Gleason scores\(^{[49]}\). Hence, differences occur in researches studying the character and appearance of definite stem cell and progenitor cell markers in prostate cancer cells.
Ugolkov et al. described that OCT4 nuclear staining expression was evidently linked with benign prostatic conditions, and not in prostatic cancer. In our work, OCT4 higher expression was found in the NPCA and BPH samples; however, significant differences were observed in its expression between NPCA and BPH cases. Instead, Rasti et al. demonstrated that renal cell cancer cases with higher OCT4 and NANOG (transcription factor in embryonic stem cells) expressions level in cancer tissues had suggestively lower survival rate and metastasis-free survival range.

Latest researches designate that miRNAs show a substantial part in stem cell regulation, comprising prostatic cancer stem cells, and may clarify part of the molecular regulatory mechanisms of cancer stem cells. The unusual appearance of miRNAs in tumor proposes that they role as either tumor-suppressor or oncogenes. miRNAs like miR-134, miR-296, and miR-470 are shared in regulation of target genes crucial for pluripotency and stem cell function comprising OCT4, SOX2, and NANOG.

OCT4 in prostatic cancer is essential because of its obvious role in carcinogenesis and tumor progression. Supplementary, OCT4 isoforms need to be inspected distinctly in pathological labs via particular antibodies touching each antigen isoform and suitable confirmation by molecular biology procedures. Additionally, OCT4B is a valued but not dependent marker of good disease prognosis and its estimation in the specimen may be vital for defining the most appropriate medical and operating attitude for cases with prostatic cancer.

Detection of OCT4 in tumor cells and tissues indicated its enrichment in a subpopulation of undifferentiated tumor-initiating cells that critically account for tumor initiation, metastasis, and resistance to anticancer therapies through its participation in various tumor-initiating cells functions such as its self-renewal and survival, epithelial-mesenchymal transition and metastasis, and drug resistance development is implicated from considerable OCT4 knockdown and overexpression-based studies.

CONCLUSIONS

This study provided evidence that:
1. Over expression of OCT4 in normal tissue around prostatic carcinoma than benign tissue in BPH.
2. Increasing age is one of important common causes of both BPH and prostatic cancer in addition to other epidemiological and pathophysiological causes.

ACKNOWLEDGEMENTS

This work was not supported by research grants.

CONFLICTS OF INTEREST

There are no conflicts of interest.

REFERENCES


الملخص العربي

التعبير عن علامة الخلايا الجذعية OCT4 في البروستات الحميدة فرط التنسيج والأنسجة الطبيعية حول سرطان البروستاتا في عينة من المرضى العراقيين

خالدة إبراهيم نونيل، وصفى محمد إبراهيم، باسم شهاب أحمد،
أحمد باهر حميدة، نيران حاتم خميس، سامح سمير عقيل

أفرع التشريح، 2 فرع الأمراض، كلية الطب، الجامعة المستنصرية، بغداد

الهدف: أمراض البروستاتا (حميدة وخبيثة) منتشرة على نطاق واسع في العالم. تضخم البروستاتا الحميد هو مرض مزمن ينتج عن تضخم البروستاتا، مما يؤدي إلى شكاوى من المسالك البولية السفلى. من ناحية أخرى، البروستاتا السرطان، هو ثاني أكثر السرطانات شيوعًا بين الرجال ورابع سرطان يحدث بشكل عام. يُشار إليه باسم عامل OCT4 النسيج المزمن ثمانية أوكتامير، ويُعرف أيضًا باسم POU5F1 (عامل نسخ فئة POU) في البشر بواسطة الجين POU5F1. هذا البروتين مفصل تحليليًا في التجديد الذاتي لخلايا جذعية جنينية غير متمايزة. على هذا النحو، تم تصميم عملنا لتقييم الفحص المناعي الكيميائي لتعبير OCT4 في الظهارة البروستاتية في حالات تضخم البروستاتا الحميد وتضخم البروستاتا الخبيثة.

المرضى والطرق: تم الحصول على عينات البروستاتا من 50 مريضا بسرطان البروستاتا و50 مريضا بسرطان البروستاتا. تم إدارة عينات للفحص الكيميائي المناعي لتعبير OCT4.

النتائج: كشف التحليل الإحصائي عن اختلاف كبير في نسبة التلطيخ بين مجموعة BPH ومجموعة NPCA P = 0.009، وكان هناك تعبير تلطيخ كبير في نسبة التلطيخ بين BPH ومجموعة NPCA P = 0.000. هناك ارتفاع كبير في النتيجة الإجمالية L-4 BPH BPH P = 0.036. BPH BPH BPH

الاستنتاجات: يتم التعبير عن BPH BPH في الأنسجة الطبيعية حول سرطان البروستاتا بالمقارنة مع الأنسجة الحميدة في OCT4 كمؤشر للخلايا الجذعية لجين نسيجية البروستاتا. وبالتالي يمكن استخدام OCT4 BPH BPH BPH BPH BPH BPH.